EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths

Описание к видео EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths

The EMPA-KIDNEY trial has demonstrated that empagliflozin reduces the risk of kidney disease progression or death from cardiovascular disease by 28% in people with chronic kidney disease.

Oxford Population Health are a world-leading research institute that investigates the causes and prevention of diseases.

Read more: https://bit.ly/3U7L4j8

Комментарии

Информация по комментариям в разработке